Originally published February 4 2005
Johnson & Johnson's stock falls as bad news about Reminyl hits the street
by Mike Adams, the Health Ranger, NaturalNews Editor
Johnson & Johnson's drug for the treatment of mild to moderate Alzheimer's has shown to increase mortality rate in a clinical study, causing Johnson & Johnson's stock to fall. The clinical trial was to determine if Reminyl could treat cognitive impairment in Alzheimer's sufferers, though Johnson & Johnson has decided not to apply for an additional use for the drug. However, it is still considered to be an effective treatment for those with mild to moderate Alzheimer's
J&J submits risk report of Reminyl - Stock value of Johnson & Johnson Pharmaceutical Company has fallen down from 64 cents to 61.85 as the company unveiled the risks carried by its drug Reminyl.
The company has submitted the study report to the FDA.
Reminyl is a cholinesterase inhibitor that is extracted from daffodil bulbs.
It boosts the levels of acetylcholine, a chemical that transmits nerve signals in the brain.
Johnson & Johnson earns about US$200 million a year from the drug.
The study conducted by J&J attempted to check whether the drug could be used for treating cognitive impairment that leads to memory loss and may develop into Alzheimer's disease.
Observations made by the researchers in the last two years during the course of the study revealed that patients taking Reminyl showed higher death rate than those on placebo.
15 patients taking Reminyl died compared with five taking the placebo.
Although the drug is approved in 69 countries as an effective treatment on mild to moderate conditions of Alzheimer, it is not yet approved for treating cognitive impairment.
The company has said that they are not planning to make any application for this use of the drug.
Carol Goodrich spokeswoman for the company said "the health authorities that are reviewing this data ...
are still supporting its use for the approved indication, which is mild to moderate Alzheimer's disease."
Health Canada's spokeswoman Carole Saindon, said data is not yet completely analyzed and they would keep the public informed as new developments surface.
She said that, "it's very important that patients don't stop taking the medication without consulting their doctor first."
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml